Back to results

Noninvasive Biomarkers of Metabolic Liver Disease 1.1

Primary Purpose

Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver

Status

Completed

Phase

Not Applicable

Locations

United States

Study Type

Interventional

Intervention

Ultrasound based shear wave speed and fat quantification methods

Blood collection

Physical measurements

Clinical history and medication reviews

About this trial

This is an interventional diagnostic trial for Nonalcoholic Steatohepatitis

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Adult (age ≥ 18 years)
Known or suspected NAFLD based on prior biopsy ≤ 36 months consistent with NAFLD OR
Abnormal ALT (>30 U/L for men, > 19 U/L for women) without other common causes such as HCV, HBV, AND meets criteria within 36 months for ATP III criteria (2005 revision) for metabolic syndrome with any 3 of the 5:

Waist circumference (WC) > 102 cm (M) or > 88 cm (F)

Fasting glucose ≥ 100 mg/dL or Rx
TG≥150mg/dLorRx
SBP > 130 mmHg
DBP>85mmHg or Rx
Able and willing to participate, including maintaining steady-state: physical activity, alcohol use, medications
Classifiable into one of the following enrollment categories by FIB-4 (ALT, AST, platelets, date of birth) collected at screening visit if not available already within 3 months prior:

Low likelihood of advanced fibrosis: FIB-4 ≤ 1.3 (about one-third of enrolled participants, minimum 8, maximum 18), Intermediate likelihood of advanced fibrosis: 1.3 < FIB-4 < 2.67 (about one-third of enrolled participants, minimum 8, maximum 18), High likelihood of advanced fibrosis: FIB-4 ≥ 2.67: (about one-third of enrolled participants, minimum 8, maximum 18)

Exclusion Criteria:

Liver disease other than NAFLD
Excess alcohol consumption (≥ 2 units/day for women and ≥ 3 units/day for men)
Current diagnosis of drug induced liver injury
Receiving drug or placebo in treatment trial now or within 30 days
Weight loss or gain of ≥ 5 kg in prior 3 months
Other factors that in the judgment of the principal investigator might preclude study completion
Women who state they are pregnant. Women who state they are pregnant will be excluded in an abundance of caution, since pregnancy might increase intra-abdominal pressure which in turn might affect the assessment of the different-day reproducibility coefficient of ultrasound and VCTE measurements. Women who state they might be pregnant will be required to do a urine pregnancy test to establish eligibility.
Patients with active implants such as pacemakers or defibrillators or any other contraindication to ultrasound or VCTE scanning.

Sites / Locations

UC San Diego
Massachusetts General Hospital

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

MGH and UCSD Study subjects

Arm Description

This study will enroll patients with suspected or confirmed diagnosis of NAFLD. Based on protocol-specified FIB-4 values, about one-third are expected to have low, one-third to have intermediate, and one-third to have high likelihood of advanced fibrosis. Sex: 50:50 - Note- no stratification will be done based on sex Age: ≥ 18 yrs Demographic group: Patients with a high probability of NAFLD based on the eligibility criteria General health status: Patients with suspected or confirmed diagnosis of NAFLD Geographic location: Boston, MA (greater metropolitan areas) and San Diego, CA (greater metropolitan areas)

Outcomes

Primary Outcome Measures

Evaluation of Pooled Different-day, Different-operator Reproducibility of Shear Wave Speed Measurements

The same research subject undergoes multiple shear wave elastography measurements (measured in m/s) on multiple ultrasound imaging devices and transient elastography at two visits (baseline + up to 7 days) with different operators. Elastographic measurements are recorded. The median shear wave velocity value (in m/s) is computed for each ultrasound imaging device and is displayed by the transient elastography device. The ultrasound machine measurements are pooled and the pooled different day-different operator reproducibility coefficient for the group of ultrasound machines is computed. The reproducibility coefficient for transient elastography is computed separately. The pooled different-day, different-operator reproducibility coefficient of ultrasound measurements of shear wave speed, is reported in the outcome measure data table section.

Different-day, Different-operator Reproducibility Coefficient of Transient Elastography Based Shear Wave Speed Measurements

The same research subject undergoes multiple shear wave elastography measurements (measured in m/s) on multiple ultrasound imaging devices and transient elastography at two visits (baseline + up to 7 days) with different operators. Elastographic measurements are recorded. The median shear wave velocity value (in m/s) is computed for each ultrasound imaging device and is displayed by the transient elastography device. The ultrasound machine measurements are pooled and the pooled different day-different operator reproducibility coefficient for the group of ultrasound machines is computed. The reproducibility coefficient for transient elastography is computed separately. The pooled different-day, different-operator reproducibility coefficient of transient elastography measurements (in m/s unit), is reported in the outcome measure data table section.

Secondary Outcome Measures

Evaluation of Pooled Same-day, Same-operator Repeatability of Shear Wave Speed (SWS)

The same research subject undergoes multiple SWE measurements (in m/s) on multiple devices and transient elastography (TE) at two visits (in 7 days) with different operators. For this outcome measure, the same-day same-operator repeatability is estimated on repeated measurements performed on the same device by the same operator at the same visit. For example, the following structure is followed for a subject; Day1 (Device A, Device B, Device C, TE, Repeated Device A, Repeated Device B), Day2 (Device A, Device B, Device C, TE, Repeated Device C, Repeated TE). The median SWS value (in m/s) is computed for each ultrasound device and is displayed by the TE device. The pooled same-day, same-operator repeatability coefficient of ultrasound measurements of SWS, is reported in the outcome measure data table section.

Evaluation of Pooled Different-scanner, Same-day Reproducibility of Shear Wave Elastography.

The same research subject undergoes multiple shear wave elastography measurements (measured in m/s) on multiple ultrasound imaging devices and transient elastography at two visits (baseline + up to 7 days) with different operators. The median shear wave velocity value (in m/s) is computed for each ultrasound imaging device and is displayed by the transient elastography device. The reproducibility coefficient of measurements obtained across different ultrasound devices on the same day by the same operator is computed. For example, the following structure is followed for a study subject; Day1 (Device A, Device B, Device C, Transient elastography, Repeated Device A, Repeated Device B), Day2 (Device A, Device B, Device C, Transient elastography, Repeated Device C, Repeated transient elastography).The pooled different-scanner, same-day reproducibility coefficient of ultrasound measurements of SWS, is reported in the outcome measure data table section.

Evaluation of Same-day, Same-operator Repeatability of Transient Elastography

Same day same operator repeat median TE measures expressed in m/s are compared and the repeatability is estimated. For example, the following structure is followed for a study subject; Day1 (Device A, Device B, Device C, Transient elastography, Repeated Device A, Repeated Device B), Day2 (Device A, Device B, Device C, Transient elastography, Repeated Device C, Repeated transient elastography), which allows estimation of same-day same operator repeatability.

Full Information

NCT ID

NCT04828551

First Posted

March 24, 2021

Last Updated

June 18, 2023

Sponsor

Massachusetts General Hospital

Collaborators

University of California, San Diego, Foundation for the National Institutes of Health

1. Study Identification

Unique Protocol Identification Number

NCT04828551

Brief Title

Noninvasive Biomarkers of Metabolic Liver Disease 1.1

Official Title

Noninvasive Biomarkers of Metabolic Liver Disease 1.1

Study Type

Interventional

2. Study Status

Record Verification Date

June 2023

Overall Recruitment Status

Completed

Study Start Date

March 18, 2021 (Actual)

Primary Completion Date

November 20, 2021 (Actual)

Study Completion Date

November 20, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Principal Investigator

Name of the Sponsor

Massachusetts General Hospital

Collaborators

University of California, San Diego, Foundation for the National Institutes of Health

4. Oversight

Studies a U.S. FDA-regulated Drug Product

Studies a U.S. FDA-regulated Device Product

Yes

Product Manufactured in and Exported from the U.S.

Data Monitoring Committee

5. Study Description

Brief Summary

NIMBLE is a comprehensive collaborative effort to standardize, compare, validate, and advance the regulatory qualification of imaging and circulating biomarkers to diagnose and stage nonalcoholic steatohepatitis (NASH), and to predict and assess response to therapeutic intervention (https://fnih.org/what-we-do/biomarkers-consortium/programs/nimble). This study focuses on estimating the repeatability and reproducibility of ultrasound elastography-based biomarkers across a range of fibrosis stages.

Detailed Description

Study 1.1, is a prospective, two-center, short-term cross-sectional study to assess the reproducibility and repeatability of a set of specified ultrasound-based quantitative imaging biomarkers. The primary focus will be on imaging biomarkers of the liver fibrosis component of nonalcoholic fatty liver disease (NAFLD), rather than the steatosis or inflammation component. The rationale is that the fibrosis component is linked most closely to survival and other clinical outcomes. Study 1.1 will also collect data to explore vendor- or device-specific investigational biomarkers on other components of NAFLD such as steatosis and possibly inflammation.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver

7. Study Design

Primary Purpose

Diagnostic

Study Phase

Not Applicable

Interventional Study Model

Single Group Assignment

Masking

None (Open Label)

Masking Description

Study participants will not be randomized to individual treatment groups. To ensure a uniform distribution of scanner combinations, participants will follow a block-allocation pattern with different scanner combinations for different participants, however, patients and operators will not be blinded to ultrasound scanners being used. All efforts will be made to keep ultrasound operators blinded to clinical and laboratory data, however, it is not believed that this will significantly affect the ultrasound acquisition. The Visit 2 operator will be asked to not review the Visit 1 exam results. Central analysts will be blinded to key clinical and laboratory findings to minimize potential bias. Blinding of the central analysts will be outlined in a separate Image Review Charter.

Allocation

N/A

Enrollment

40 (Actual)

8. Arms, Groups, and Interventions

Arm Title

MGH and UCSD Study subjects

Arm Type

Other

Arm Description

Intervention Type

Device

Intervention Name(s)

Ultrasound based shear wave speed and fat quantification methods

Intervention Description

Ultrasound based imaging parameters will be collected from all patients in two visits. These will include but may not be limited to SWE results, Quantitative ultrasound parameters,where available,including Attenuation Coefficient, Backscatter Coefficient, Shear Wave Dispersion, Speed of Sound, Ultrasound derived fat fraction Conventional Bmode (gray-scale) and Doppler ultrasound images,including An image of the liver and right kidney on the same image for hepatorenal index calculation Right liver lobe for skin to liver capsule distance calculation Portal vein Doppler for portal vein pulsatility index measurement VCTE and Controlled Attenuation Parameter measurements with the Fibroscan system

Intervention Type

Diagnostic Test

Intervention Name(s)

Blood collection

Intervention Description

Blood will be collected by trained phlebotomists at each site using routine methods and standard collection tubes. Total volume is expected to be about 10 mL or less Blood collected at MGH will be analyzed by the MGH clinical laboratory. Blood collected at UCSD will be analyzed by the UCSD clinical laboratory. Blood results obtained within the 3-month interval prior to the screening visit at the MGH or UCSD laboratories will be considered acceptable for study analyses and may be used at PI discretion. For each laboratory, the normal ranges for each blood test will be recorded and filed

Intervention Type

Other

Intervention Name(s)

Physical measurements

Intervention Description

Height will be recorded at Screening. Weight and vital signs will be recorded at each visit. Body mass index will be calculated at each visit. All measurements will be made by trained coordinators using standard and calibrated instruments.

Intervention Type

Other

Intervention Name(s)

Clinical history and medication reviews

Intervention Description

The following questionnaires will be administered at Screening: Medical history questionnaire Medication use questionnaire Alcohol consumption questionnaire Physical activity questionnaire The following questionnaires will be administered at Visit 1 and Visit 2: Interim medical history questionnaire Change in medication use questionnaire Change in alcohol consumption will be recorded using a modified version of the alcohol use followback. Alcohol use for the 7 day period prior to Visit 1 and for all days between Visit 1 and Visit 2 will be recorded. Change in physical activity questionnaire

Primary Outcome Measure Information:

Title

Evaluation of Pooled Different-day, Different-operator Reproducibility of Shear Wave Speed Measurements

Description

Time Frame

(2 visits, baseline + up to 7 days). Outcome measure will be assessed after pooling measurements from all study subjects.

Title

Different-day, Different-operator Reproducibility Coefficient of Transient Elastography Based Shear Wave Speed Measurements

Description

The same research subject undergoes multiple shear wave elastography measurements (measured in m/s) on multiple ultrasound imaging devices and transient elastography at two visits (baseline + up to 7 days) with different operators. Elastographic measurements are recorded. The median shear wave velocity value (in m/s) is computed for each ultrasound imaging device and is displayed by the transient elastography device. The ultrasound machine measurements are pooled and the pooled different day-different operator reproducibility coefficient for the group of ultrasound machines is computed. The reproducibility coefficient for transient elastography is computed separately. The pooled different-day, different-operator reproducibility coefficient of transient elastography measurements (in m/s unit), is reported in the outcome measure data table section.

Time Frame

(2 visits, baseline + up to 7days). Outcome measure will be assessed after pooling all measurements from all study subjects.

Secondary Outcome Measure Information:

Title

Evaluation of Pooled Same-day, Same-operator Repeatability of Shear Wave Speed (SWS)

Description

Time Frame

(2 visits, baseline + up to 7days). Outcome measure will be assessed after pooling measurements from all study subjects.

Title

Evaluation of Pooled Different-scanner, Same-day Reproducibility of Shear Wave Elastography.

Description

The same research subject undergoes multiple shear wave elastography measurements (measured in m/s) on multiple ultrasound imaging devices and transient elastography at two visits (baseline + up to 7 days) with different operators. The median shear wave velocity value (in m/s) is computed for each ultrasound imaging device and is displayed by the transient elastography device. The reproducibility coefficient of measurements obtained across different ultrasound devices on the same day by the same operator is computed. For example, the following structure is followed for a study subject; Day1 (Device A, Device B, Device C, Transient elastography, Repeated Device A, Repeated Device B), Day2 (Device A, Device B, Device C, Transient elastography, Repeated Device C, Repeated transient elastography).The pooled different-scanner, same-day reproducibility coefficient of ultrasound measurements of SWS, is reported in the outcome measure data table section.

Time Frame

(2 visits, baseline + up to 7days). Outcome measure will be assessed after pooling all measurements from all study subjects.

Title

Evaluation of Same-day, Same-operator Repeatability of Transient Elastography

Description

Time Frame

(2 visits, baseline + up to 7days). Outcome measure will be assessed after pooling all measurements from all study subjects.

10. Eligibility

Sex

All

Minimum Age & Unit of Time

18 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: Adult (age ≥ 18 years) Known or suspected NAFLD based on prior biopsy ≤ 36 months consistent with NAFLD OR Abnormal ALT (>30 U/L for men, > 19 U/L for women) without other common causes such as HCV, HBV, AND meets criteria within 36 months for ATP III criteria (2005 revision) for metabolic syndrome with any 3 of the 5: Waist circumference (WC) > 102 cm (M) or > 88 cm (F) Fasting glucose ≥ 100 mg/dL or Rx TG≥150mg/dLorRx SBP > 130 mmHg DBP>85mmHg or Rx Able and willing to participate, including maintaining steady-state: physical activity, alcohol use, medications Classifiable into one of the following enrollment categories by FIB-4 (ALT, AST, platelets, date of birth) collected at screening visit if not available already within 3 months prior: Low likelihood of advanced fibrosis: FIB-4 ≤ 1.3 (about one-third of enrolled participants, minimum 8, maximum 18), Intermediate likelihood of advanced fibrosis: 1.3 < FIB-4 < 2.67 (about one-third of enrolled participants, minimum 8, maximum 18), High likelihood of advanced fibrosis: FIB-4 ≥ 2.67: (about one-third of enrolled participants, minimum 8, maximum 18) Exclusion Criteria: Liver disease other than NAFLD Excess alcohol consumption (≥ 2 units/day for women and ≥ 3 units/day for men) Current diagnosis of drug induced liver injury Receiving drug or placebo in treatment trial now or within 30 days Weight loss or gain of ≥ 5 kg in prior 3 months Other factors that in the judgment of the principal investigator might preclude study completion Women who state they are pregnant. Women who state they are pregnant will be excluded in an abundance of caution, since pregnancy might increase intra-abdominal pressure which in turn might affect the assessment of the different-day reproducibility coefficient of ultrasound and VCTE measurements. Women who state they might be pregnant will be required to do a urine pregnancy test to establish eligibility. Patients with active implants such as pacemakers or defibrillators or any other contraindication to ultrasound or VCTE scanning.

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Anthony E Samir, MD, MPH

Organizational Affiliation

Massachusetts General Hospital

Official's Role

Principal Investigator

First Name & Middle Initial & Last Name & Degree

Kathryn Fowler, MD

Organizational Affiliation

UC San Diego

Official's Role

Principal Investigator

Facility Information:

Facility Name

UC San Diego

City

San Diego

State/Province

California

ZIP/Postal Code

92103

Country

United States

Facility Name

Massachusetts General Hospital

City

Boston

State/Province

Massachusetts

ZIP/Postal Code

02114

Country

United States

12. IPD Sharing Statement

Plan to Share IPD

Yes

Learn more about this trial

Noninvasive Biomarkers of Metabolic Liver Disease 1.1

We'll reach out to this number within 24 hrs